Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of OSE2101 versus docetaxel after immunotherapy failure in metastatic NSCLC
NL-OMON60049Phase 3Recruiting
- Sponsor
- OSE Immunotherapeutics
- Start
- Dec 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing OSE2101 with Docetaxel (2 arms). Primary endpoint: Overall survival. Started Dec 2024; status: recruiting.
02
Drugs
Tedopidocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60049.